Pharmacotherapy of hepatic encephalopathy in cirrhosis

Bibliography

• Ferenci P, Lockwood A, Mullen K, Hepatic encephalopathy- Definition, Nomenclature, Diagnosis, and Quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35(3):716-21
   Google Scholar
• Sherlock S. Chronic portal-systemic encephalopathy: update 1987. Gut 1987;28:1043-8
   Google Scholar
• Nance FC, Kline DG. Eck's fistula encephalopathy in germ-free dogs. Ann Surg 1971;174:856-61
   Google Scholar
• Warren KS, Newton WL. Portal and peripheral blood ammonia concentrations in germ-free and conventional guinea pigs. Am J Pysiol 1959;197:717-20
   PubMed Web of Science ®Google Scholar
• Weber FJL, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77:235-40
   PubMed Web of Science ®Google Scholar
• Olde Damink SW, Jalan R, Redhead DN, Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002;36:1163-71
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004;39:939-43
   Google Scholar
• James LA, Lunn PG, Middleton S, Distribution of glutaminase and glutamine synthase activities in the human gastrointestinal tract. Clin Sci 1998;94:313-9
   PubMedGoogle Scholar
• Romero-Gomez M, Ramos-Guerrero R, Grande L, Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004;41:49-54
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M. Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2005;20:319-25
   Google Scholar
• Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995;15:133-59
   PubMed Web of Science ®Google Scholar
• Hawkins RA, Jessy J, Mans AM, Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol 1994;368:125-34
   Google Scholar
• Taylor L, Liu X, Newsome W, Isolation and characterization of the promoter region of the rat kidney-type glutaminase gene. Biochim Biophys Acta 2001;1518:132-6
   Google Scholar
• Elgadi KM, Meguid RA, Qian M, Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1999;1:51-62
   PubMed Web of Science ®Google Scholar
• Del Campo JA, Jover M, Royo JL, A microsatellite in the promoter region of the GLS gene predicts the risk of hepatic encephalopathy: functional analysis using luciferase reporter. Hepatology 2009;50:320A
   Google Scholar
• Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004;106:467-74
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Davies NA, Williams R, Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-54
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Greco F, Barone G, Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52:3259-65
   PubMed Web of Science ®Google Scholar
• Cauli O, Rodrigo R, Piedrafita B, Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 2007;46:514-9
   PubMed Web of Science ®Google Scholar
• Wright G, Jalan R. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: pandora's box? Hepatology 2007;46:291-4
   Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):13-27
   Google Scholar
• Testa R, Eftimiadi C, Sukkar GS, A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-92
   PubMedGoogle Scholar
• De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979-81
   PubMedGoogle Scholar
• Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-18
   PubMed Web of Science ®Google Scholar
• Mas A, Rodés J, Sunyer L, Comparison of rifaximin and actitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:527-8
   Google Scholar
• Festi D, Vestito A, Mazzella G, Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73(Suppl 1):94-101
   Google Scholar
• Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacology 2008;28:1019-32
   Google Scholar
• Bass NM, Mullen KD, Sanyal A, Rifaximin Treatment in Hepatic Encephalopathy. N Eng J Med 2010;362:1071-81
   PubMed Web of Science ®Google Scholar
• Leevy B, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Schi 2007;52:737-41
   PubMed Web of Science ®Google Scholar
• Maclayton DO, Eaton-Maxwell Al. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009;43:77-84
   Google Scholar
• Sharma P, Sharma BC, Puri V, An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008;20:506-11
   PubMed Web of Science ®Google Scholar
• Loguercio C, Abbiati R, Rinaldi M, Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23:39-46
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Gargante MP, Malaguarnera G, Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010;22(2):199-206
   Google Scholar
• Bajaj JS, Saeian K, Christensen KM, Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008;103(7):1707-15
   Google Scholar
• Liu Q, Duan ZP, Ha DK, Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-9
   PubMed Web of Science ®Google Scholar
• Masini A, Efrati C, Merli M, Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of non-absorbable disaccharides on small intestine ammonia generation. Am J Gastroenterol 1999;94:3323-7
   Google Scholar
• Jiang Q, Jiang XH, Zheng MH, Rifaximin versus non-absorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064-70
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046
   PubMed Web of Science ®Google Scholar
• Prasad S, Dhiman RK, Duseja A, Lactulose improves cognitive function and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-59
   PubMed Web of Science ®Google Scholar
• Sharma BC, Sharma P, Agrawal A, Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-91
   PubMed Web of Science ®Google Scholar
• Sharma P, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 2009;29:1365-71
   Google Scholar
• Dasarathy S, Yang Y, Muc S, Ammonia causes elevated skeletal muscle myostatin and reduced myoblast proliferation and differentiation. Hepatology 2009;50:22A
   Google Scholar
• Córdoba J, López-Hellín J, Planas M, Normal protein diet for episodic hepatic encephalopathy. J Hepatol 2004;41:38-43
   PubMed Web of Science ®Google Scholar
• Les I, Planas M, Cardenas G, Effects of the proteins of the diet in patients with cirrhosis and prior episode of hepatic encephalopathy. A long-term randomized study. Hepatology 2009;50:24A
   Google Scholar
• Stauch S, Kircheis G, Adler G, Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-64
   PubMed Web of Science ®Google Scholar
• Kircheis G, Nilius R, Held C, Therapeutic efficacy of L-ornitine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: result of a placebo-controlled, double blind study. Hepatology 1997;25:1351-60
   PubMed Web of Science ®Google Scholar
• Jiang Q, Jiang XH, Zheng MH, L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009;24:9-14
   Google Scholar
• Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006;44:788-94
   PubMed Web of Science ®Google Scholar
• Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004;(2):CD002798
   Google Scholar
• Barbaro G, Di Lorenzo G, Soldini M, Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-8
   PubMed Web of Science ®Google Scholar
• Riggio O, Efrati C, Catalano C, High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42:1158-65
   PubMed Web of Science ®Google Scholar
• Boixadera H, Tomasello A, Quiroga S, Successful embolization of a spontaneous mesocaval shunt using the Amplatzer vascular plug II. Cardiovasc Intervent Radiol 2010. (In press)
   Google Scholar
• Maleux G, Heye S, Verslype C, Management of transjugular intrahepatic porto-systemic shunt induced refractory hepatic encephalopathy with the parallel technique: results of a clinical follow-up study. J Vasc Interv Radiol 2007;18:986-92
   Google Scholar
• Bureau C, Garcia-Pagan JC, Otal P, Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75
   PubMed Web of Science ®Google Scholar
• Randolph C, Hilsabeck R, Kato A, Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:629-35
   PubMed Web of Science ®Google Scholar
• Kircheis G, Wettstein M, Timmermann L, Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-66
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M. Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. J Hepatol 2007;47:10-1
   Google Scholar
• Romero-Gómez M, Córdoba J, Jover R, Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007;45:879-85
   PubMed Web of Science ®Google Scholar